Verteporfin is being explored for hair regeneration, with unofficial trials and updates shared online. Efforts are being made to encourage more surgeons to trial verteporfin for donor hair regeneration.
The conversation discusses using ecklonia cava as a natural alternative to finasteride for hair loss. Users share their experiences and opinions on its effectiveness.
The conversation discusses whether using 0.1% topical finasteride alongside 0.5 mg oral finasteride is excessive, with suggestions to choose either oral or topical treatment. The user also uses 5% minoxidil and mentions concerns about alcohol-based solutions due to seborrheic dermatitis.
The user has been using 1mg finasteride, 5% minoxidil, Nizoral, and a derma stamp weekly for two months to treat hair loss. They are experiencing good results, with some skin flaking from microneedling.
The conversation is about the progress of verteporfin in hair loss trials, with users expressing curiosity about its effectiveness and updates. Specific treatments mentioned include FUE (Follicular Unit Extraction) combined with verteporfin, with one reported case of donor area regrowth after a year, and three patients being monitored post-treatment by Dr. Bloxham with monthly updates on YouTube.
The user plans to use an electric microneedling pen for hair loss, set to penetrate 0.6mm to 0.8mm, and apply rosemary oil in jojoba oil post-treatment. They also intend to use 5% Minoxidil daily, followed by a blend of rosemary, peppermint, and jojoba oils.
New hair loss treatments, including Breezula, VDPHL01, and PP405, are nearing Phase 3 trials, offering hope for effective solutions. Current treatments like finasteride and minoxidil remain effective, but early intervention is crucial.
PP405 is a potential hair loss treatment showing promising early results, with hopes for market release by 2028, but skepticism remains due to inconclusive data and past disappointments with similar products. Current treatments like Minoxidil and Finasteride have side effects, leading some to anticipate PP405 as a safer alternative, though its effectiveness compared to placebo is debated.
A user proposed genetically engineering scalp stem cells to stop androgen receptors from causing hair loss. Others discussed the feasibility, existing research, and potential issues with this approach, including targeting the correct cells and unintended effects.
PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.